Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 359-368 , June 2008

Arginine vasopressin vs. terlipressin in the treatment of shock states

  • Mervyn Singer, MBBS, MD, FRCP(Lon), FRCP(Edin) (Professor of Intensive Care Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +44 207 679 6714; Fax: +44 207 679 6952.

References 

  1. Padkin A, Goldfrad C, Brady AR, et al. Epidemiology of severe sepsis occurring in the first 24hrs in intensive care units in England, Wales, and Northern Ireland. Critical Care Medicine. 2003;31:2332–2338
  2. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. The New England Journal of Medicine. 2003;348:1546–1554
  3. Available from: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/finaldeaths03/finaldeaths03.htm
  4. Annane D, Bellissant E, Cavaillon JM. Septic shock. The Lancet. 2005;365:63–78
  5. Rudiger A, Singer M. Sepsis-induced cardiac depression. Critical Care Medicine. 2007;35:1599–1608
  6. O'Brien AJ, Wilson AJ, Singer M, Clapp L. Temporal variation in endotoxin-induced vascular hyporeactivity in a rat mesenteric artery organ culture model. British Journal of Pharmacology. 2001;133:351–360
  7. Buckley JF, Singer M, Clapp LH. Role of KATP channels in sepsis. Cardiovascular Research. 2006;72:220–230
  8. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122–1125
  9. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Critical Care Medicine. 2003;31:1752–1758
  10. Wilson MF, Brackett DJ, Hinshaw LB, et al. Vasopressin release during sepsis and septic shock in baboons and dogs. Surgery Gynecology & Obstetrics. 1981;153:869–872
  11. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Critical Care Medicine. 2004;32:21–30
  12. Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Medicine. 2001;27:1416–1421
  13. Russell JA, Walley KR, Singer J, et al., for the VASST Investigators  Vasopressin versus norepinephrine infusion in patients with septic shock. The New England Journal of Medicine. 2008;358:877–887
  14. Barrett L, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Critical Care Medicine. 2007;35:33–40
  15. Nilsson G, Lindblom P, Ohlin M, et al. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs under Experimental and Clinical Research. 1990;16:307–314
  16. Forsling ML, Aziz LA, Miller M, et al. Conversion of triglycylvasopressin to lysine-vasopressin in man. The Journal of Endocrinology. 1980;85:237–244
  17. Freeman JG, Cobden I, Lishman AH, Record CO. Controlled trial of terlipressin (‘Glypressin’) versus vasopressin in the early treatment of oesophageal varices. The Lancet. 1982;ii:66–68
  18. Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology. 1986;6:112–115
  19. Levacher S, Letoumelin P, Pateron D, et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. The Lancet. 1995;346:865–868
  20. Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology. 1998;29:565–570
  21. Uriz J, Ginès P, Cárdenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. Journal of Hepatology. 2000;33:43–48
  22. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923–930
  23. Boccara G, Ouattara A, Godet G, et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Anesthesiology. 2003;98:1338–1344
  24. Leone M, Charvet A, Delmas A, et al. Terlipressin: a new therapeutic for calcium-channel blocker overdose. Journal of Critical Care. 2005;20:114–115
  25. Zuidema X, Dünser MW, Wenzel V, et al. Terlipressin as an adjunct vasopressor in refractory hypotension after tricyclic antidepressant intoxication. Resuscitation. 2007;72:319–323
  26. Salluh JI, Martins GA, Santino MS, et al. Early use of terlipressin in catecholamine-resistant shock improves cerebral perfusion pressure in severe traumatic brain injury. Acta Anaesthesiologica Scandinavica. 2007;51:505–508
  27. Rocq N, Favier JC, Plancade D, et al. Successful use of terlipressin in post-cardiac arrest resuscitation after an epinephrine-resistant anaphylactic shock to suxamethonium. Anesthesiology. 2007;107:166–167
  28. Matok I, Vardi A, Augarten A, et al. Beneficial effects of terlipressin in prolonged pediatric cardiopulmonary resuscitation: a case series. Critical Care Medicine. 2007;35:1161–1164
  29. Vinayak BC, Birchall MA, Donovan B, Stafford ND. A randomized double-blind trial of glypressin in the management of acute epistaxis. Rhinology. 1993;31:131–134
  30. Vernersson E, Palmer B, Aberg M. Triglycyl-lysine-vasopressin or lysine-vasopressin in early excision of burns. An experimental study comparing the effects on blood loss, hemodynamics and renal function. Scandinavian Journal of Plastic and Reconstructive Surgery. 1984;18:285–290
  31. Garner WL, Thomson PD, Moore NP, et al. Effect of triglycyl-lysine-vasopressin on skin blood flow and blood loss during wound excision in patients with burns. The Journal of Burn Care & Rehabilitation. 1993;14:458–460
  32. Scharte M, Meyer J, Van Aken H, Bone HG. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Critical Care Medicine. 2001;29:1756–1760
  33. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. The Lancet. 2002;359:1209–1210
  34. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Critical Care Medicine. 2001;29:487–493
  35. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Medicine. 2004;30:597–604
  36. Leone M, Albanèse J, Delmas A, et al. Terlipressin in catecholamine-resistant septic shock patients. Shock. 2004;22:314–319
  37. Albanèse J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine. 2005;33:1897–1902
  38. Klein M, Weksler N, Borer A, et al. Terlipressin facilitates transport of septic patients treated with norepinephrine. The Israel Medical Association Journal. 2006;8:691–693
  39. Jolley DH, De Keulenaer BL, Potter A, Stephens DP. Terlipressin infusion in catecholamine-resistant shock. Anaesthesia and Intensive Care. 2003;31:560–564
  40. Fellahi JL, Bénard P, Daccache G, et al. Vasodilatory septic shock refractory to catecholamines: is there a role for terlipressin?. Annales Francaises d'Anesthesie et de Reanimation. 2003;22:631–634
  41. Matok I, Leibovitch L, Vardi A, et al. Terlipressin as rescue therapy for intractable hypotension during neonatal septic shock. Pediatric Critical Care Medicine. 2004;5:116–118
  42. Rodríguez-Núñez A, Fernández-Sanmartín M, Martinón-Torres F, et al. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Medicine. 2004;30:477–480
  43. Peters MJ, Booth RA, Petros AJ. Terlipressin bolus induces systemic vasoconstriction in septic shock. Pediatric Critical Care Medicine. 2004;5:112–115
  44. Matok I, Vard A, Efrati O, et al. Terlipressin as rescue therapy for intractable hypotension due to septic shock in children. Shock. 2005;23:305–310
  45. Rodríguez-Núñez A, López-Herce J, Gil-Antón J, et al., for the RETSPED Working Group of the Spanish Society of Pediatric Intensive Care  Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Critical Care (London, England). 2006;10:R20
  46. Meyer S, Gortner L, McGuire W, et al. Vasopressin in catecholamine-refractory shock in children. Anaesthesia. 2008;63:228–234
  47. Yildizdas D, Yapicioglu H, Celik U, et al. Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children. Intensive Care Medicine. 2008;34:511–517
  48. Medel J, Boccara G, Van de Steen E, et al. Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia?. Anesthesia & Analgesia. 2001;93:53–55
  49. Schmitt W, Wagner-Thiessen E, Lux G. Ischaemic colitis in a patient treated with glypressin for bleeding oesophageal varices. Hepatogastroenterology. 1987;34:134–136
  50. Foresti V, Parisio E, Ungaro A, et al. Terlipressin-induced metabolic acidosis. Recenti Progressi in Medicina. 1991;82:240–241
  51. Stéphan F, Paillard F. Terlipressin-exacerbated hypokalaemia. The Lancet. 1998;351:1249–1250
  52. Dunwoodie E, Jowett S. Terlipressin causing a hyponatraemic seizure. Scandinavian Journal of Gastroenterology. 2007;42:665
  53. Lee JS, Lee HS, Jung SW, et al. A case of peripheral ischemic complication after terlipressin therapy. The Korean Journal of Gastroenterology. 2006;47:454–457
  54. Donnellan F, Cullen G, Hegarty JE, McCormick PA. Ischaemic complications of Glypressin in liver disease: a case series. British Journal of Clinical Pharmacology. 2007;64:550–552
  55. Borrego R, López-Herce J, Mencía S, et al. Severe ischemia of the lower limb and of the intestine associated with systemic vasoconstrictor therapy and femoral arterial catheterization. Pediatric Critical Care Medicine. 2006;7:267–269
  56. Boerma EC, van der Voort PH, Ince C. Sublingual microcirculatory flow is impaired by the vasopressin-analogue terlipressin in a patient with catecholamine-resistant septic shock. Acta Anaesthesiologica Scandinavica. 2005;49:1387–1390
  57. Hansen EF, Strandberg C, Højgaard L, et al. Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs. Journal of Hepatology. 1999;30:503–510
  58. Blei AT, Groszmann RJ, Gusberg R, Conn HO. Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Digestive Diseases and Sciences. 1980;25:688–694
  59. Asfar P, Pierrot M, Veal N, et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Critical Care Medicine. 2003;31:215–220
  60. Asfar P, Hauser B, Iványi Z, et al. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Critical Care Medicine. 2005;33:373–380
  61. Westphal M, Stubbe H, Sielenkämper AW, et al. Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Medicine. 2003;29:301–308
  62. Bröking K, Lange M, Morelli A, et al. Employing dobutamine as a useful agent to reverse the terlipressin-linked impairments in cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep. Shock. 2008;29:71–77
  63. Escorsell A, Bandi JC, Moitinho E, et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. Journal of Hepatology. 1997;26:621–627
  64. Freeman JG, Barton JR, Record CO. Haemodynamic responses to 1.25 and 2mg of terlipressin intravenously in man. Alimentary Pharmacology & Therapeutics. 1988;2:361–367
  65. Merkel C, Bianco S, Bolognesi M, et al. Effect of triglycyl-lysin-vasopressin on quantitative liver function tests in patients with cirrhosis. American Journal of Gastroenterology. 1992;87:1580–1586
  66. Morelli A, Ertmer C, Lange M, Westphal M. Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better?. Intensive Care Medicine. 2007;33:1669–1670
  67. Michel F, Thomachot L, David M, et al. Continuous low-dose infusion of terlipressin as a rescue therapy in meningococcal septic shock. American Journal of Emergency Medicine. 2007;25:863;e1–2
  68. Umgelter A, Reindl W, Schmid RM, Huber W. Continuous terlipressin infusion in patients with persistent septic shock and cirrhosis of the liver. Intensive Care Medicine. 2008;34:390–391
  69. Lange M, Morelli A, Ertmer C, et al. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock. 2007;28:623–629

PII: S1521-6896(08)00029-3

doi: 10.1016/j.bpa.2008.03.005

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 359-368 , June 2008

Article Tools